Adamis Pharmaceuticals Corporation, formerly Cellegy Pharmaceuticals, Inc., is a specialty pharmaceutical company. The Company's wholly owned subsidiary, Biosyn, Inc. has a portfolio of product candidates known as microbicides. Biosyn's product candidates, which include both contraceptive and non-contraceptive microbicides, are used intravaginally. Biosyn's product candidates include Savvy, which underwent Phase III clinical trials in Ghana and Nigeria for reduction in the transmission of human immunodeficiency virus/acquired immunodeficiency disease, (HIV/AIDS). Effective April 1, 2009, Cellegy Pharmaceuticals, Inc. merged with Adamis Pharmaceuticals Corporation, pursuant to which Adamis Pharmaceuticals Corporation (Adamis) became a wholly owned subsidiary of the Company.

Ask: N/A   Bid: N/A   Market Capitalization: 12.5M   Average Daily Volume: 0   Earnings/Share: -0.155   P/E Ratio: N/A   PEG Ratio: N/A   Change From 52-week High: N/A   Price/Book: N/A   Stock Exchange: OTC BB